{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:01:37Z","timestamp":1768554097763,"version":"3.49.0"},"posted":{"date-parts":[[2021,5,3]]},"group-title":"HIV\/AIDS","reference-count":88,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cotrimoxazole and isoniazid preventive therapy (CPT, IPT) have been shown to be efficacious therapies for the prevention of opportunistic infections and tuberculosis (TB) among people living with human immunodeficiency virus (HIV). Despite governments\u2019 efforts to translate World Health Organization recommendations into practice, implementation remains challenging. This review aimed to explore and compare CPT and IPT with respect to similarities and differences of barriers identified across high TB\/HIV burden countries. A secondary objective was to identify facilitators for implementing both preventive therapies.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched MEDLINE, Web of Science and SCOPUS databases for peer-reviewed literature published before September 2020. We extracted and synthesized our findings using Maxqda software. We applied framework synthesis in conjunction with metasummary to compare both therapies with respect to similarities and differences of barriers identified across seven health system components (in line with the modified WHO\u2019s Framework for action). Protocol registration: PROSPERO (CRD42019137778).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>We identified four hundred and eighty-two papers, of which we included forty for review. Although most barrier themes were identical for both preventive therapies, we identified seven intervention-specific themes. Like for CPT, barriers identified for IPT were most frequently classified as \u2018service delivery-related barriers\u2019 and \u2018patient &amp; community-related barriers\u2019. \u2018Health provider-related barriers\u2019 played an additional important role for implementing of IPT. Most facilitators identified referred to health system strengthening activities.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>For researchers with limited working experience in high TB\/HIV burden countries, this review can provide valuable insights about barriers that may arise at different levels of the health system. For policymakers in high TB\/HIV burden countries, this review offers strategies for improving the delivery of IPT (or any newer therapy regimen) for the prevention of TB. Based on our findings, we suggest initial and continuous stakeholder involvement, a focus on the efficient use and reinforcement of existing resources for health.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2021.04.30.21256370","type":"posted-content","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T20:00:28Z","timestamp":1620072028000},"source":"Crossref","is-referenced-by-count":0,"title":["Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid \u2013 preventive therapies for people living with HIV"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-5017","authenticated-orcid":false,"given":"Pia","family":"M\u00fcller","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-1294","authenticated-orcid":false,"given":"Lu\u00eds","family":"Velez Lap\u00e3o","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2021050508200499000_2021.04.30.21256370v1.1","unstructured":"UNAIDS. Global HIV & AIDS statistics - 2020 fact sheet. 2020. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"2021050508200499000_2021.04.30.21256370v1.2","unstructured":"World Health Organization. Global Tuberculosis Report 2020. 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240013131."},{"key":"2021050508200499000_2021.04.30.21256370v1.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00655-2019"},{"key":"2021050508200499000_2021.04.30.21256370v1.4","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: Module 1. Prevention: Tuberculosis preventive treatment 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment.","DOI":"10.30978\/TB2021-2-86"},{"key":"2021050508200499000_2021.04.30.21256370v1.5","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. chapter 5: Clinical guidelines: Managing common coinfections and comorbidities.: World Health Organization; 2016. Available from: https:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/."},{"issue":"4","key":"2021050508200499000_2021.04.30.21256370v1.6","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2352-3018(15)00005-3","article-title":"Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis","volume":"2","year":"2015","journal-title":"The Lancet HIV"},{"key":"2021050508200499000_2021.04.30.21256370v1.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4031-2"},{"key":"2021050508200499000_2021.04.30.21256370v1.8","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12919"},{"issue":"11","key":"2021050508200499000_2021.04.30.21256370v1.9","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","article-title":"Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial","volume":"5","year":"2017","journal-title":"The Lancet Global Health"},{"key":"2021050508200499000_2021.04.30.21256370v1.10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000171.pub3"},{"issue":"1","key":"2021050508200499000_2021.04.30.21256370v1.11","first-page":"30","article-title":"Provisional WHO\/UNAIDS Secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV\/AIDS in Africa","volume":"1","author":"World Health Organization","year":"2000","journal-title":"African Health Sciences"},{"key":"2021050508200499000_2021.04.30.21256370v1.12","unstructured":"WHO\/ UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV 1998. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/64509\/WHO_TB_98.255.pdf?sequence=1."},{"key":"2021050508200499000_2021.04.30.21256370v1.13","unstructured":"World Health Organization. Tuberculosis. Key facts 2020. 14 October 2020:[Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis."},{"key":"2021050508200499000_2021.04.30.21256370v1.14","doi-asserted-by":"publisher","DOI":"10.5114\/hivar.2018.80263"},{"key":"2021050508200499000_2021.04.30.21256370v1.15","doi-asserted-by":"publisher","DOI":"10.2147\/dhps.s89115"},{"issue":"1","key":"2021050508200499000_2021.04.30.21256370v1.16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12630-008-9007-4","article-title":"Posing the research question: not so simple","volume":"56","year":"2009","journal-title":"Canadian journal of anaesthesia"},{"issue":"3","key":"2021050508200499000_2021.04.30.21256370v1.17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/wvn.12134","article-title":"A guide to writing a qualitative systematic review protocol to enhance evidence-based practice in nursing and health care","volume":"13","year":"2016","journal-title":"Worldviews on Evidence-Based Nursing"},{"key":"2021050508200499000_2021.04.30.21256370v1.18","unstructured":"Joanna Briggs Institute. JBI Reviewer\u2019s Manual. Chapter 8: Mixed methods systematic reviews. Section 8.5.1 Mixed methods systematic review using a convergent integrated approach to synthesis and integration. 2017 [cited 1]. Available from: https:\/\/wiki.jbi.global\/display\/MANUAL\/8.5.1+++Mixed+methods+systematic+review+using+a+CONVERGENT+INTEGRATED+approach+to+synthesis+and+integration."},{"key":"2021050508200499000_2021.04.30.21256370v1.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2021050508200499000_2021.04.30.21256370v1.20","unstructured":"Cumpston M , Chandler J . Chapter IV: updating a review 2019. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-iv."},{"key":"2021050508200499000_2021.04.30.21256370v1.21","unstructured":"Hong QN , Pluye P , F\u00e0bregues S , Bartlett G , Boardman F , Cargo M , et al. Mixed methods appraisal tool (MMAT), version 2018. User guide. 2018. Available from: http:\/\/mixedmethodsappraisaltoolpublic.pbworks.com\/w\/file\/fetch\/127916259\/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf."},{"key":"2021050508200499000_2021.04.30.21256370v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.06.020"},{"key":"2021050508200499000_2021.04.30.21256370v1.23","unstructured":"Hannes K . Chapter 4: Critical appraisal of qualitative research: Cochrane Collaboration Qualitative Methods Group, 2011; 2011. Available from: http:\/\/cqrmg.cochrane.org\/supplemental-handbook-guidance."},{"issue":"1","key":"2021050508200499000_2021.04.30.21256370v1.24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/nur.20176","article-title":"Using qualitative metasummary to synthesize qualitative and quantitative descriptive findings","volume":"30","year":"2007","journal-title":"Research in nursing & health"},{"issue":"11","key":"2021050508200499000_2021.04.30.21256370v1.25","first-page":"1230","volume":"66","year":"2013","journal-title":"Synthesizing evidence on complex interventions: how meta-analytical, qualitative, and mixed-method approaches can contribute"},{"key":"2021050508200499000_2021.04.30.21256370v1.26","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000391023.03037.1f"},{"key":"2021050508200499000_2021.04.30.21256370v1.27","unstructured":"World Health Organization. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies: World Health Organization; 2010. Available from: https:\/\/www.who.int\/healthinfo\/systems\/WHO_MBHSS_2010_full_web.pdf."},{"key":"2021050508200499000_2021.04.30.21256370v1.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072712"},{"key":"2021050508200499000_2021.04.30.21256370v1.29","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2006.059394"},{"key":"2021050508200499000_2021.04.30.21256370v1.30","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0694-5"},{"key":"2021050508200499000_2021.04.30.21256370v1.31","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v15i1.7"},{"key":"2021050508200499000_2021.04.30.21256370v1.32","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-015-1159-y"},{"key":"2021050508200499000_2021.04.30.21256370v1.33","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-352"},{"key":"2021050508200499000_2021.04.30.21256370v1.34","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-2136-0"},{"key":"2021050508200499000_2021.04.30.21256370v1.35","doi-asserted-by":"crossref","unstructured":"Mwambete KD , Kamuhabwa AA . Resistance of commensal intestinal Escherichia coli and other enterics to co-trimoxazole and commonly used antibiotics in HIV\/AIDS patients. Clinical Microbiology: Open Access. 2013.","DOI":"10.4172\/2327-5073.1000134"},{"key":"2021050508200499000_2021.04.30.21256370v1.36","doi-asserted-by":"publisher","DOI":"10.2147\/dhps.s119073"},{"key":"2021050508200499000_2021.04.30.21256370v1.37","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0753"},{"issue":"8","key":"2021050508200499000_2021.04.30.21256370v1.38","first-page":"955","article-title":"Health system barriers affecting the implementation of collaborative TB-HIV services in Uganda","volume":"13","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021050508200499000_2021.04.30.21256370v1.39","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001378"},{"key":"2021050508200499000_2021.04.30.21256370v1.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069548"},{"key":"2021050508200499000_2021.04.30.21256370v1.41","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/tru110"},{"key":"2021050508200499000_2021.04.30.21256370v1.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2010.02576.x"},{"key":"2021050508200499000_2021.04.30.21256370v1.43","doi-asserted-by":"publisher","DOI":"10.4103\/jgid.jgid_138_18"},{"issue":"3","key":"2021050508200499000_2021.04.30.21256370v1.44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00002030-199509030-00008","article-title":"Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre","volume":"9","year":"1995","journal-title":"AIDS"},{"key":"2021050508200499000_2021.04.30.21256370v1.45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103205"},{"issue":"Suppl 5","key":"2021050508200499000_2021.04.30.21256370v1.46","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/01.aids.0000391022.95412.a6","article-title":"The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB\/HIV in Rio (THRio) study","volume":"24","year":"2010","journal-title":"AIDS"},{"key":"2021050508200499000_2021.04.30.21256370v1.47","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.158"},{"key":"2021050508200499000_2021.04.30.21256370v1.48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018435"},{"key":"2021050508200499000_2021.04.30.21256370v1.49","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000000895"},{"key":"2021050508200499000_2021.04.30.21256370v1.50","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2017.1283390"},{"key":"2021050508200499000_2021.04.30.21256370v1.51","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02675-6"},{"key":"2021050508200499000_2021.04.30.21256370v1.52","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000278"},{"key":"2021050508200499000_2021.04.30.21256370v1.53","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0378"},{"key":"2021050508200499000_2021.04.30.21256370v1.54","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000366082.68321.d6"},{"key":"2021050508200499000_2021.04.30.21256370v1.55","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.16.0836"},{"key":"2021050508200499000_2021.04.30.21256370v1.56","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0574-z"},{"key":"2021050508200499000_2021.04.30.21256370v1.57","doi-asserted-by":"publisher","DOI":"10.5588\/pha.20.0003"},{"issue":"1","key":"2021050508200499000_2021.04.30.21256370v1.58","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1186\/1471-2458-11-916","article-title":"Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia","volume":"11","year":"2011","journal-title":"BMC public health"},{"key":"2021050508200499000_2021.04.30.21256370v1.59","doi-asserted-by":"publisher","DOI":"10.4102\/sajid.v34i1.10"},{"issue":"9","key":"2021050508200499000_2021.04.30.21256370v1.60","first-page":"1037","article-title":"Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania","volume":"12","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021050508200499000_2021.04.30.21256370v1.61","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199701000-00016"},{"key":"2021050508200499000_2021.04.30.21256370v1.62","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2019.1704540"},{"issue":"3","key":"2021050508200499000_2021.04.30.21256370v1.63","first-page":"263","article-title":"Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings?","volume":"9","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021050508200499000_2021.04.30.21256370v1.64","doi-asserted-by":"publisher","DOI":"10.25159\/2520-5293\/6221"},{"key":"2021050508200499000_2021.04.30.21256370v1.65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-97"},{"key":"2021050508200499000_2021.04.30.21256370v1.66","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1619661"},{"key":"2021050508200499000_2021.04.30.21256370v1.67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212035"},{"key":"2021050508200499000_2021.04.30.21256370v1.68","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024286"},{"key":"2021050508200499000_2021.04.30.21256370v1.69","unstructured":"The World Bank. World Bank country and lending groups 2021. Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"key":"2021050508200499000_2021.04.30.21256370v1.70","unstructured":"Kates J , Wexler A , Lief E . Donor government funding for HIV in low-and middle-income countries in 2019 2020. Available from: https:\/\/files.kff.org\/attachment\/Donor-Government-Funding-for-HIV-in-Low-and-Middle-Income-Countries-in-2019.pdf."},{"key":"2021050508200499000_2021.04.30.21256370v1.71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijid.2020.09.011","article-title":"Ending the epidemic of HIV\/AIDS by 2030: Will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many countries?","volume":"100","year":"2020","journal-title":"International Journal of Infectious Diseases"},{"key":"2021050508200499000_2021.04.30.21256370v1.72","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czw009"},{"issue":"2","key":"2021050508200499000_2021.04.30.21256370v1.73","doi-asserted-by":"crossref","first-page":"e1002240","DOI":"10.1371\/journal.pmed.1002240","article-title":"Evidence for scaling up HIV treatment in sub-Saharan Africa: a call for incorporating health system constraints","volume":"14","year":"2017","journal-title":"PLoS medicine"},{"key":"2021050508200499000_2021.04.30.21256370v1.74","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.09.066522"},{"key":"2021050508200499000_2021.04.30.21256370v1.75","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2014.0306"},{"key":"2021050508200499000_2021.04.30.21256370v1.76","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2020.1830296"},{"key":"2021050508200499000_2021.04.30.21256370v1.77","unstructured":"Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 31th Edition: CLSI; 2020 [cited 35]. 1-332]. Available from: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100-preorder\/."},{"key":"2021050508200499000_2021.04.30.21256370v1.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.05.026"},{"key":"2021050508200499000_2021.04.30.21256370v1.79","doi-asserted-by":"publisher","DOI":"10.1258\/004947506776593314"},{"key":"2021050508200499000_2021.04.30.21256370v1.80","doi-asserted-by":"publisher","DOI":"10.1093\/her\/cyl039"},{"key":"2021050508200499000_2021.04.30.21256370v1.81","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/15.5.471"},{"key":"2021050508200499000_2021.04.30.21256370v1.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2018.10.030"},{"issue":"sup1","key":"2021050508200499000_2021.04.30.21256370v1.83","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/21665095.2018.1511378","article-title":"EU Donors and health system strengthening: the love-hate relationship with the Global Fund","volume":"5","year":"2018","journal-title":"Development Studies Research"},{"key":"2021050508200499000_2021.04.30.21256370v1.84","unstructured":"USAID. USAID\u2019s vision for health systems strengthening 2030: Author Washington, DC; 2021. Available from: https:\/\/www.usaid.gov\/sites\/default\/files\/documents\/USAID_OHS_VISION_Report_FINAL_single_5082.pdf."},{"key":"2021050508200499000_2021.04.30.21256370v1.85","unstructured":"World Health Organization. Healthy systems for universal health coverage: a joint vision for healthy lives 2018. Available from: https:\/\/www.uhc2030.org\/fileadmin\/uploads\/uhc2030\/Documents\/About_UHC2030\/mgt_arrangemts___docs\/UHC2030_Official_documents\/UHC2030_vision_paper_WEB2.pdf."},{"key":"2021050508200499000_2021.04.30.21256370v1.86","unstructured":"Global Fund . The Global Fund Strategy 2017\u20132022: investing to end epidemics: Reliefweb; 2017. Available from: https:\/\/www.theglobalfund.org\/media\/2531\/core_globalfundstrategy2017-2022_strategy_en.pdf."},{"key":"2021050508200499000_2021.04.30.21256370v1.87","unstructured":"USAID. ADS Chapter 220: Use and Strengthening of Reliable Partner Government Systems for Implementation of Direct Assistance 2014. Available from: https:\/\/2012-2017.usaid.gov\/sites\/default\/files\/documents\/1868\/220.pdf."},{"issue":"3","key":"2021050508200499000_2021.04.30.21256370v1.88","first-page":"77","article-title":"Health system strengthening: a qualitative evaluation of implementation experience and lessons learned across five African countries","volume":"17","year":"2017","journal-title":"BMC health services research"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.04.30.21256370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:14:36Z","timestamp":1768486476000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.04.30.21256370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":88,"URL":"https:\/\/doi.org\/10.1101\/2021.04.30.21256370","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1371\/journal.pone.0251612","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2021,5,3]]},"subtype":"preprint"}}